摘要
重症急性胰腺炎(SAP)是一种高发病率和高病死率的疾病,尽管对其治疗采用多方面的综合的支持治疗,但SAP的病死率仍居高不下。近年来益生菌在临床上得到广泛应用,耐药性良好,而不良反应非常罕见。不少学者认为利用益生菌作为辅助药物应用到SAP中具有重要意义,但其临床有效性及安全性尚存在争议,该文通过查阅相关文献,对益生菌辅助治疗SAP的相关研究作一综述。
Severe acute pancreatitis(SAP)is a disease with high incidence and mortality.Despite the comprehensive treatment,the mortality of SAP is still high.In recent years,probiotics have been widely used in clinic,with good drug resistanceand rare adverse re⁃actions.Many scholars believe that the use of probiotics as adjuvant drugs in SAP is of great significance,but its clinical efficacy and safety are still controversial.This paper summarizes the relevant literature on probiotics adjuvant therapy for SAP by consulting the rel⁃evant literature.
作者
吕晋红
李晓丽
LYU Jinhong;LI Xiaoli(Graduate School of Shanxi Medical University,Taiyuan,Shanxi 030001,China;GI Medicine of The First Hospital of Shanxi Medical University,Taiyuan,Shanxi 030001,China)
出处
《安徽医药》
CAS
2024年第2期217-220,共4页
Anhui Medical and Pharmaceutical Journal
关键词
胰腺炎
急性坏死性
益生菌
机制
有效性
安全性
Pancreatitis,acute necrotizing
Probiotics
Mechanism
Effectivenes
Security
